Europeans and biotechnologies in 2010 - Winds of change?
By Nanowerk News,
Nanowerk News
| 11. 15. 2010
The European Commission has released their new report "Europeans and biotechnology in 2010 – Winds of change?" (pdf). This latest Eurobarometer survey on the Life Sciences and Biotechnology, which also specifically addresses nanotechnologies in the context of biotechnology, is based on representative samples from 32 European countries and conducted in February 2010. The report points to a new era in the relations between science and society. While entrenched views about GM food are still evident, the crisis of confidence in technology and regulation that characterised the 1990s – a result of BSE, contaminated blood and other perceived regulatory failures – is no longer the dominant perspective.
In 2010 we see a greater focus on technologies themselves: are they safe? Are they useful? And are there 'technolite'alternatives with more acceptable ethical-moral implications? Europeans are also increasingly concerned about energy and sustainability. There is no rejection of the impetus towards innovation: Europeans are in favour of appropriate regulation to balance the market, and wish to be involved in decisions about new technologies when social values are at stake.
Here is an overview...
Related Articles
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...
By Todd Feathers, The Guardian | 03.25.2024
For the last several months, a city at the heart of Silicon Valley has been training artificial intelligence to recognize tents and cars with people living inside in what experts believe is the first experiment of its kind in the...
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...